GlassScriptPhysician profile
Jason R Bisping
NPI 1295919819
$261,008.59
in general payments reported to CMS, 2019-2025
10 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $26K · 2021: $28K · 2022: $24K · 2023: $50K · 2024: $11K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Honoraria: $35K · Travel and Lodging: $6,310 · Food and Beverage: $2,607 · Consulting Fee: $720 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,408.00 |
| Honoraria | $34,525.00 |
| Travel and Lodging | $6,310.42 |
| Food and Beverage | $2,606.68 |
| Consulting Fee | $720.00 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $135,650.48 | 2019-2022 | |
| Sk Life Science, INC. | $60,463.52 | 2020-2025 | Xcopri |
| Ucb, INC. | $47,256.28 | 2019-2025 | Nayzilam |
| Sumitomo Pharma America, INC. | $16,846.21 | 2023 | Aptiom |
| Livanova USA, INC. | $600.18 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $113.13 | 2020 | |
| Supernus Pharmaceuticals, INC. | $34.91 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Abbvie INC. | $15.00 | 2023 | Vraylar |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bisping listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.